NO20043013L - Tetrahydrokinolin analoger som muskarine agonister - Google Patents

Tetrahydrokinolin analoger som muskarine agonister

Info

Publication number
NO20043013L
NO20043013L NO20043013A NO20043013A NO20043013L NO 20043013 L NO20043013 L NO 20043013L NO 20043013 A NO20043013 A NO 20043013A NO 20043013 A NO20043013 A NO 20043013A NO 20043013 L NO20043013 L NO 20043013L
Authority
NO
Norway
Prior art keywords
compounds
muscarinic agonists
tetrahydroquinoline
methods
muscarinic receptor
Prior art date
Application number
NO20043013A
Other languages
English (en)
Other versions
NO327522B1 (no
Inventor
Bo Lennart Mikael Friberg
Kristian Norup Koch
Bo-Ragnar Tolf
Niels Skjaerbaek
Original Assignee
Acadia Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acadia Pharm Inc filed Critical Acadia Pharm Inc
Publication of NO20043013L publication Critical patent/NO20043013L/no
Publication of NO327522B1 publication Critical patent/NO327522B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
NO20043013A 2001-12-28 2004-07-15 Tetrahydrokinolinanaloger, anvendelser derav samt sammensetning omfattende forbindelsen NO327522B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34472201P 2001-12-28 2001-12-28
PCT/US2002/041617 WO2003057672A2 (en) 2001-12-28 2002-12-23 Tetrahydroquinoline analogues as muscarinic agonists

Publications (2)

Publication Number Publication Date
NO20043013L true NO20043013L (no) 2004-07-28
NO327522B1 NO327522B1 (no) 2009-08-03

Family

ID=23351729

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20043013A NO327522B1 (no) 2001-12-28 2004-07-15 Tetrahydrokinolinanaloger, anvendelser derav samt sammensetning omfattende forbindelsen

Country Status (19)

Country Link
US (3) US7307075B2 (no)
EP (1) EP1461318B9 (no)
JP (1) JP4509565B2 (no)
KR (1) KR100972614B1 (no)
CN (1) CN100402032C (no)
AT (1) ATE304533T1 (no)
AU (1) AU2002359875B2 (no)
BR (1) BR0215430A (no)
CA (1) CA2470578C (no)
DE (1) DE60206198T2 (no)
DK (1) DK1461318T3 (no)
ES (1) ES2251624T3 (no)
IL (2) IL162616A0 (no)
MX (1) MXPA04006281A (no)
NO (1) NO327522B1 (no)
NZ (1) NZ533566A (no)
RU (1) RU2292346C2 (no)
WO (1) WO2003057672A2 (no)
ZA (1) ZA200405024B (no)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ533566A (en) 2001-12-28 2007-03-30 Acadia Pharm Inc Tetrahydroquinoline analogues as muscarinic agonists
US7550459B2 (en) * 2001-12-28 2009-06-23 Acadia Pharmaceuticals, Inc. Tetrahydroquinoline analogues as muscarinic agonists
JP2006521399A (ja) * 2003-03-28 2006-09-21 アカディア ファーマシューティカルズ，インコーポレーテッド 疼痛管理用ムスカリンｍ１受容体アゴニスト
WO2006137485A1 (ja) * 2005-06-24 2006-12-28 Toyama Chemical Co., Ltd. 新規な含窒素複素環化合物およびその塩
EP2258359A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
JP2009506069A (ja) 2005-08-26 2009-02-12 ブレインセルス，インコーポレイティド ムスカリン性受容体調節による神経発生
US7985756B2 (en) 2005-10-21 2011-07-26 Braincells Inc. Modulation of neurogenesis by PDE inhibition
WO2007053596A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
GB0607952D0 (en) * 2006-04-21 2006-05-31 Minster Res Ltd Novel treatment
GB0607949D0 (en) * 2006-04-21 2006-05-31 Minster Res The Ltd Mono and combination therapy
WO2007134136A2 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
WO2007134077A2 (en) 2006-05-09 2007-11-22 Braincells, Inc. 5 ht receptor mediated neurogenesis
EP2049120A4 (en) * 2006-07-31 2011-09-07 Janssen Pharmaceutica Nv UROTENSIN II RECEPTOR ANTAGONISTS
EP2068872A1 (en) 2006-09-08 2009-06-17 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
JP2011529966A (ja) 2008-08-02 2011-12-15 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ウロテンシンｉｉ受容体拮抗物質
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
CN104039321B (zh) 2011-11-18 2017-02-22 赫普泰雅治疗有限公司 药物化合物
GB201404922D0 (en) 2014-03-19 2014-04-30 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201513743D0 (en) 2015-08-03 2015-09-16 Heptares Therapeutics Ltd Muscarinic agonists
GB201519352D0 (en) 2015-11-02 2015-12-16 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201617454D0 (en) 2016-10-14 2016-11-30 Heptares Therapeutics Limited Pharmaceutical compounds
GB201810239D0 (en) 2018-06-22 2018-08-08 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201819960D0 (en) 2018-12-07 2019-01-23 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201819961D0 (en) 2018-12-07 2019-01-23 Heptares Therapeutics Ltd Pharmaceutical compounds
GB202020191D0 (en) 2020-12-18 2021-02-03 Heptares Therapeutics Ltd Pharmaceutical compounds
WO2023114224A1 (en) 2021-12-13 2023-06-22 Sage Therapeutics, Inc. Combination of muscarinic receptor positive modulators and nmda positive allosteric modulators

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3365457A (en) * 1964-05-08 1968-01-23 Sterling Drug Inc N [(1-, 2-, 3-indolyl)-lower alkyl]-1, 5-iminocycloalkane and-1, 5-iminocycloalkene derivatives
US3324137A (en) * 1964-05-08 1967-06-06 Sterling Drug Inc N-[indolyl-lower-alkanoyl]-1, 5-iminocycloalkanes and -iminocycloalkenes
JPS63290821A (ja) * 1987-05-25 1988-11-28 Otsuka Pharmaceut Co Ltd 抗不整脈剤
JP2886570B2 (ja) * 1989-09-29 1999-04-26 エーザイ株式会社 縮合ヘテロ環を有する化合物
US5149815A (en) * 1991-04-29 1992-09-22 American Home Products Corporation N-substituted-2-aminoquinolines
US5378698A (en) * 1991-10-21 1995-01-03 Shionogi & Co., Ltd. Benzothiazepine derivatives
US5457099A (en) * 1992-07-02 1995-10-10 Sawai Pharmaceutical Co., Ltd. Carbostyril derivatives and antiallergic agent
DE4228095A1 (de) 1992-08-24 1994-03-03 Asta Medica Ag Neue 4,5-Dihydro-4-oxo-pyrrolo[1,2-a]chinoxaline und entsprechende Aza-analoga und Verfahren zu deren Herstellung
US5707798A (en) * 1993-07-13 1998-01-13 Novo Nordisk A/S Identification of ligands by selective amplification of cells transfected with receptors
TW448161B (en) * 1994-07-14 2001-08-01 Otsuka Pharma Co Ltd Cyclic amide derivatives
ATE221520T1 (de) * 1995-09-29 2002-08-15 Glaxo Wellcome Spa Tetrahydrochinoline als nmda antagonisten
GB9617305D0 (en) * 1996-08-17 1996-09-25 Glaxo Wellcome Spa Heterocyclic compounds
EP0934932A4 (en) 1996-08-22 2002-06-26 Meiji Seika Kaisha CHINOLINE DERIVATIVES AND PSYCHOTROPES MEDIUM
US5919750A (en) * 1997-07-24 1999-07-06 Akzo Nobel Nv Fabric softener composition
IL137656A0 (en) * 1998-03-31 2001-10-31 Warner Lambert Co Benzoxazinones/benzothiazinones as serine protease inhibitors
AU762726B2 (en) * 1998-03-31 2003-07-03 Acadia Pharmaceuticals, Inc. Compounds with activity on muscarinic receptors
ES2223588T3 (es) * 1999-10-13 2005-03-01 Banyu Pharmaceutical Co., Ltd. Derivados de imidazolidinona sustituidos.
EP1246817B1 (en) 1999-12-30 2004-06-23 H. Lundbeck A/S 4-phenyl-1-piperazinyl, -piperidinyl and -tetrahydropyridyl derivatives
IL151533A0 (en) * 2000-02-29 2003-04-10 Mitsubishi Pharma Corp Novel cyclic amide derivatives
RU2269523C2 (ru) * 2000-04-28 2006-02-10 Акадиа Фармасьютикалз, Инк. Мускариновые агонисты
US6951849B2 (en) * 2001-10-02 2005-10-04 Acadia Pharmaceuticals Inc. Benzimidazolidinone derivatives as muscarinic agents
NZ533566A (en) 2001-12-28 2007-03-30 Acadia Pharm Inc Tetrahydroquinoline analogues as muscarinic agonists
JP2006521399A (ja) 2003-03-28 2006-09-21 アカディア ファーマシューティカルズ，インコーポレーテッド 疼痛管理用ムスカリンｍ１受容体アゴニスト

Also Published As

Publication number Publication date
CN1635891A (zh) 2005-07-06
DE60206198D1 (de) 2005-10-20
BR0215430A (pt) 2004-12-14
JP4509565B2 (ja) 2010-07-21
NZ533566A (en) 2007-03-30
WO2003057672A2 (en) 2003-07-17
US20060199810A1 (en) 2006-09-07
AU2002359875B2 (en) 2009-01-08
HK1074573A1 (zh) 2005-11-18
DK1461318T3 (da) 2006-01-09
NO327522B1 (no) 2009-08-03
US20030176418A1 (en) 2003-09-18
WO2003057672A3 (en) 2003-11-13
CA2470578A1 (en) 2003-07-17
EP1461318B1 (en) 2005-09-14
DE60206198T2 (de) 2006-06-14
EP1461318B9 (en) 2005-12-28
CA2470578C (en) 2010-10-12
CN100402032C (zh) 2008-07-16
IL162616A0 (en) 2005-11-20
KR100972614B1 (ko) 2010-07-27
ZA200405024B (en) 2005-07-27
RU2292346C2 (ru) 2007-01-27
RU2004123203A (ru) 2006-01-20
ES2251624T3 (es) 2006-05-01
US7576100B2 (en) 2009-08-18
US7576078B2 (en) 2009-08-18
US7307075B2 (en) 2007-12-11
US20060199813A1 (en) 2006-09-07
IL162616A (en) 2011-06-30
EP1461318A2 (en) 2004-09-29
JP2005519060A (ja) 2005-06-30
AU2002359875A1 (en) 2003-07-24
MXPA04006281A (es) 2004-09-27
KR20040070287A (ko) 2004-08-06
ATE304533T1 (de) 2005-09-15

Similar Documents

Publication Publication Date Title
DK1461318T3 (da) Tetrahydroquinolinanaloge som muscariniske agonister
TW200634006A (en) Tetrahydroquinoline analogues as muscarinic agonists
NO20042964L (no) Spiroazasykliske forbindelser som monoaminreseptormodulatorer
DE69926806D1 (de) N-ureidoalkylpiperidine als modulatoren der aktivität der chemokinrezeptoren
EA200900828A1 (ru) Соединения и композиции в качестве ингибиторов активности каннабиноидного рецептора 1
DE69926919D1 (de) N-ureidoalkylpiperidine als modulatoren der aktivität der chemokinrezeptoren
EA200100780A1 (ru) Антагонисты tweak и рецептора tweak и их использование для лечения иммунологических заболеваний
UY26130A1 (es) Compuestos para tratar la obesidad
EA200401309A1 (ru) Тризамещённые гетероарилы и способы их получения и применения
BR0308243A (pt) Composto, formulação farmacêutica, e, métodos de tratar diabetes, doença de alzheimer, e de inibir gsk-3 em um mamìfero
ATE433447T1 (de) Pyrimiidinverbindungen
DE60327999D1 (de) Azolylaminoazine als inhibitoren von proteinkinasen
AR030893A1 (es) Uso combinado de inhibidores de acetilcolinesterasa y agonistas inversos de gabaa para el tratamiento de trastornos cognitivos
BR0314053A (pt) Pirazolopiridinas e métodos de obtenção e uso das mesmas
NO20035025L (no) Anvendelse av osteopontin for behandling og/eller for a hindre nevrologiske sykdommer, samt farmasoytisk sammensetning omfattende osteopontin eller en antagonist med osteopontinaktivitet.
DE60019586D1 (de) Myostatin genpromoter und inhibierung dessen aktivierung
DE602006013191D1 (de) Substituierte 1h-benzimidazol-4-carbonsäureamide sind wirksame parp-inhibitoren
UA95103C2 (ru) Замещенные арилсульфонамиды в качестве противовирусных средств
ATE443044T1 (de) Tace inhibitoren
NO20014855D0 (no) N-(2-fenyl-4-aminobutyl)-1-naftamider som neurokinin-1- reseptorantagonister
DK1250337T3 (da) Substituerede homopiperidinylbenzimidazol-analoger som fundus-relaksanter
ATE274515T1 (de) Pyrazolopyridinderivate
EA200600115A1 (ru) Производные 2-аминобензойной кислоты
EA200600534A1 (ru) Сочетание ингибитора обратного захвата серотонина и амоксапина

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees